Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|2|620-626

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.2, 2015-02, pp. : 620-626

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1036-1047

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reply to: “Sorafenib or 90Y loaded resin microsphere radioembolization for locally‐advanced hepatocellular carcinoma, what should we trust?”

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1780-1781

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib‐ or 90Y‐loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1779-1780

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite